MOHMMED NOGUD MARGNI M.D
Prescription History 1417113713
Surgery - Vascular Surgery in Flint, MI


Quality Rating: 29.46 out of 100 score

NPI Status: Active since August 06, 2008

Contact Information

1 HURLEY PLZ
FLINT, MI
ZIP 48503
Phone: (810) 262-6555
Fax: (810) 262-9787

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MOHMMED NOGUD MARGNI M.D, an active Vascular Surgery specialist practicing in Flint, MI. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 335 documented patient claims. Among these therapy options, the most frequently utilized medication is Clopidogrel, which accounts for 250 claims alone.

Medication Index

No matching medications currently found on file.

Clopidogrel

Generic Formulation: Clopidogrel BisulfateSpecialty: General Surgery
Provider Metrics Summary
Total Claims 250
30-Day Fills 678.1
Days Supply 20,302
MI State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills126.7
Peer Average Days Supply3,767
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 354.5% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,288.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.15

State Avg Cost Per Claim

$16.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.

Therapeutic Applications

Clopidogrel is used to prevent heart attacks and strokes in persons with heart disease (recent heart attack), recent stroke, or blood circulation disease (peripheral vascular disease). It is also used with aspirin to treat new/worsening chest pain (new heart attack, unstable angina) and to keep blood vessels open and prevent blood clots after certain procedures (such as cardiac stent). Clopidogrel works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It helps keep blood flowing smoothly in your body.

Eliquis

Generic Formulation: ApixabanSpecialty: General Surgery
Provider Metrics Summary
Total Claims 26
30-Day Fills 38.0
Days Supply 1,140
MI State Average Benchmarks
Peer Average Claims76.0
Peer Average 30-Day Fills135.2
Peer Average Days Supply3,873
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.8% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,952.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$728.93

State Avg Cost Per Claim

$879.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Xarelto

Generic Formulation: RivaroxabanSpecialty: General Surgery
Provider Metrics Summary
Total Claims 59
30-Day Fills 79.5
Days Supply 2,302
MI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills80.8
Peer Average Days Supply2,339
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.9% more claims than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $48,769.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$826.61

State Avg Cost Per Claim

$965.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MOHMMED NOGUD MARGNI M.D provides transparency into local medical care patterns within Flint, MI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Vascular Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.